[Treatment of asthenic syndrome in patients with chronic brain ischemia: results of the non-interventional observational program TRIUMPH].
OBJECTIVE
To assess the severity of asthenic syndrome (AS) in chronic brain ischemia (CBI) in primary health care settings.


METHODS
The study included 1170 patients with brain ischemia, aged 45-65 years, treated with phenotropil in dose 100 mg during 2 and 3 months. Clinical examination and MFI-20 subscales were administered. RESULTS AND СONCLUSION: The high incidence of asthenic syndrome was observed across all MFI-20 subscales. The decrease in asthenic syndrome severity was significant already in the end of the first month of treatment with phenotropil. Such dynamics maintained to the end of the second and third month of treatment. More than 2-fold decrease in the severity of asthenia symptoms was achieved in all subgroups 3 months after treatment. More rapid and apparent decrease in asthenic syndrome was observed in younger patients.
GOU VPO 'Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova', Moskva.
A I
AI
Fedin
GOU VPO 'Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova', Moskva.
É Iu
ÉI
Solov'eva
GOU VPO 'Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova', Moskva.
O P
OP
Mironova
GOU VPO 'Rossiĭskiĭ natsional'nyĭ issledovatel'skiĭ meditsinskiĭ universitet im. N.I. Pirogova', Moskva.
A V
AV
Fedotova
D000368:Aged; D000369:Aged, 80 and over; D001247:Asthenia / Q000188:drug therapy* / Q000209:etiology*; D002545:Brain Ischemia / Q000150:complications*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009440:Neurasthenia / Q000188:drug therapy* / Q000209:etiology*; D010889:Piracetam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013577:Syndrome; D016896:Treatment Outcome
C037917:4-phenylpiracetam; D010889:Piracetam